Spectral Medical IncOTC Pink - Current Information:EDTXFView on Canadian Exchange
- LAST PRICE0.3100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.3100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Apr 10, 2024
Spectral Medical Provides Tigris Trial Update, from 7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
7:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 2, 2024
DJ Spectral Medical Appoints Paul Walker Chairman, Anthony Bihl to Retire, from 8:21AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:21AM ET on Tuesday Apr 02, 2024 by Dow Jones*DJ Spectral Medical Chairman Anthony Bihl III to Retire From Board of Directors >EDT.T, from 8:01AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:01AM ET on Tuesday Apr 02, 2024 by Dow JonesSpectral Medical Chair to Retire From the Board of Directors, from 8:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
Mar 28, 2024
*DJ Spectral Medical 4Q Rev C$365,000 >EDT.T, from 4:02PM ET on Thursday Mar 28, 2024 by Dow Jones
4:02PM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Spectral Medical Inc | 122.6M | -7.6x | --- |
Global Pharmatech Inc | 59.3M | -1.6x | --- |
NDT Pharmaceuticals Inc | 52.8M | 0.0x | --- |
Zhong Yuan Bio-Technology Holdings Ltd | 79.6M | 392.2x | --- |
Odonate Inc | 50.0M | -1,258.5x | --- |
Bright Green Corp | 37.6M | -2.7x | --- |
Company Information
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX has been on the market in many countries outside the United States and has been used in more than 340,000 patients to date. It is engaged in the development of biochemical markers for the clinical syndrome known as septic shock. It is also continuing its legacy business of manufacturing and selling certain reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.
Contact Information
- Headquarters
- 135 The West Mall, Unit 2TORONTO, ON, Canada M9C 1C2
- Phone
- 416-626-3233
- Fax
- 416-626-3233
Executives
- Chairman of the Board, President
- Paul Walker
- Chief Executive Officer, Director
- Chris Seto
- Chief Medical Officer
- John Kellum
- Director
- David Feigal
- Independent Director
- Anthony Bihl
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $89.7M |
|---|---|
Revenue (TTM) | $1.2M |
Shares Outstanding | 278.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.85 |
EPS | $-0.04 |
Book Value | $-0.04 |
P/E Ratio | -7.6x |
Price/Sales (TTM) | 76.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -970.46% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
